Interferon beta-1a Completed Phase 4 Trials for Relapsing Remitting Multiple Sclerosis (RRMS) Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT01201343Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients
NCT02064816A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis
NCT00206648An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS
NCT01142466A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
NCT01534182Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
NCT01317004Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change
NCT01144052Natalizumab De-escalation With Interferon Beta-1b
NCT00078338Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
NCT00168766Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS
NCT00317941Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif
NCT00367484Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis
NCT00493116Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
NCT00492466Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies
NCT00534261Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?
NCT02587065Plegridy Satisfaction Study in Participants